Hypoperfusion intensity ratio is associated with follow-up infarct volume in medium vessel occlusions: A multicenter multinational study
- PMID: 40829981
- DOI: 10.1016/j.neurot.2025.e00713
Hypoperfusion intensity ratio is associated with follow-up infarct volume in medium vessel occlusions: A multicenter multinational study
Abstract
Medium vessel occlusion (MeVO) contributes significantly to acute ischemic stroke (AIS). The hypoperfusion intensity ratio (HIR), reflecting collateral circulation via the ratio of Tmax >10s to Tmax >6s volumes, predicts infarct progression in large-vessel occlusions but is unstudied in MeVOs. In this multicenter, multinational retrospective study, we evaluated consecutive patients with MeVO who underwent mechanical thrombectomy with or without intravenous thrombolysis. Inclusion required available follow-up imaging and pretreatment CT perfusion. Follow-up infarct volume (FIV) was measured on CT or MRI 12-36 h post-procedure. Univariable and multivariable linear regression models were used to identify predictors of FIV, with HIR as the primary variable of interest. Among 147 patients (median age 75 years, 57 % female), univariable analysis showed HIR was significantly associated with larger FIV (β = 80 mL; p < 0.001). After adjusting for confounders, HIR remained independently associated with FIV (β = 40 mL; p < 0.001). Tmax >10 s showed the strongest correlation with FIV (r = 0.56; p < 0.001). These findings suggest that higher HIR correlates with larger infarct volumes, underscoring the prognostic role of collateral failure in MeVO and highlighting HIR as a potential imaging marker to guide treatment and outcome prediction.
Keywords: Acute Ischemic Stroke; CT Perfusion (CTP); Collateral Circulation; Distal Occlusions; Follow-Up Infarct Volume (FIV); Hypoperfusion Intensity Ratio (HIR); Mechanical Thrombectomy; Medium Vessel Occlusion (MeVO); Stroke Ou; Tmax Thresholds.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Dr. Regenhardt serves on a DSMB for a trial sponsored by Rapid Medical, serves as site PI for studies sponsored by Penumbra and Microvention, and receives stroke research grant funding from the National Institutes of Health, Society of Vascular and Interventional Neurology, and Heitman Stroke Foundation. Dr. Guenego reports consultancy for Rapid Medical and Phenox, not directly related to the present work. Dr. Clarençon reports conflicts of interest with Medtronic, Balt Extrusion (consultant), ClinSearch (core lab), Penumbra, Stryker (payment for reading) and Artedrone (Board); all not directly related to the present work. Dr. Henninger received support from W81XWH-19-PRARP-RPA form the CDMRP/DoD, NS131756 and U24NS113844 from the NINDS, and NR020231 from the NINR and received compensation from Myrobalan, Inc. and General Dynamics during the conduct of this study unrelated to this work. Dr. Liebeskind is consultant as Imaging Core Lab to Cerenovus, Genentech, Medtronic, Stryker, Rapid Medical. Dr. Yeo reports Advisory work for AstraZeneca, Substantial support from NMRC Singapore and is a medical advisor for See-mode, Cortiro and Sunbird Bio, with equity in Ceroflo. All unrelated to the present work. Dr. Griessenauer reports a proctoring agreement with Medtronic and research funding by Penumbra. Dr. Marnat reports conflicts of interest with Microvention Europe, Stryker Neurovascular, Balt (consulting), Medtronic, Johnson & Johnson and Phenox (paid lectures), all not directly related to the present work. Dr. Puri is a consultant for Medtronic Neurovascular, Stryker Neurovascular, Balt, Q'Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical, he received research grants from NIH, Microvention, Cerenovus, Medtronic Neurovascular and Stryker Neurovascular, and holds stocks in InNeuroCo, Agile, Perfuze, Galaxy and NTI. Dr. Tjoumakaris is a consultant for Medtronic and Microvention (funds paid to institution, not personally). Dr. Jabbour is a consultant for Medtronic, Microvention and Cerus. Tobias Faizy was funded by the Else-Kröner-Fresenius-Stiftung (EKFS): Project Number: 2023_EKES.02. Dr. Siegler has served as a consultant for AstraZeneca, Bayer, and Novartis; has received research funding from the National Institutes of Health (R61NS135583, R01NS114632), Viz.ai, Philips, and Medtronic; compensation from the American Heart Association for editorial services; serves on the Editorial Board for Neurology and Stroke: Vascular and Interventional Neurology. Dr.Nguyen reports Associate Editor of Stroke; Advisory board of Brainomix, Aruna Bio; Speaker for Genentech, Kaneka; consulting for Medtronic.
LinkOut - more resources
Full Text Sources
